$MEND is partnering with Cyclica to advance drug discovery For those into the wellness and or health tech sectors, Nurosene Health Inc. ($MEND.C $MNNDF) had some good news yesterday announcing that it is partnering with Cyclica Inc. in hopes of advancing the drug discovery pipeline.
This partnership will leverage NetraHealthAtlas (one of $MEND's core proprietary AI tools) to accelerate drug discovery for neurodegenerative diseases.
$MEND will lead in the discovery phase of the research process by identifying specific drug targets demonstrating the power of NetraHealthAtlas to accelerate drug target identification while reducing the costs of bringing a drug to market.
Specifically, NetraHealthAtlas will generate lists of protein targets from patient-level genetic data which will allow Cyclica's platform to predict molecular candidates for selected protein targets. These protein targets can then be tested to see if these can treat/alter the disease.
Glad to see that $MEND is continuing to create partnerships that really show off the power of its AI Tech. I can think of another wellness app that has this much science behind it.
Today $MEND closed stable @ $0.72/share
MC is $24.316M
https://ca.finance.yahoo.com/news/nurosene-cyclica-partner-develop-novel-192200226.html